Skip to main navigation Skip to search Skip to main content

A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with Lunacaftor in Conbination With Ivacaftor in Subjects Aged 6 Years and Oder with Cystic Fibrosis; Homozygous for the CF508del-CFTR mutation

Project: Research

Project Details

StatusFinished
Effective start/end date08/11/15 → 08/10/19

Funding

  • Vertex Pharmaceuticals Incorporated: $156,113.91